Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

615
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice" [Eur. J. Cancer 238 (May) (2026) 116686].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States.

NPJ breast cancer·2026
Same author

Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Real-World Characterization and Treatment Patterns of Patients with Desmoid Tumors at an Academic Center in the United States.

Cancer research communications·2026
Same author

Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database.

Clinical lung cancer·2026
Same author

Racial differences in biomarkers, treatment, and outcomes in HR+/HER2- metastatic breast cancer in the United States.

NPJ breast cancer·2026

Related Experiment Video

Updated: Mar 13, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Ceritinib: A primer for pharmacists.

Trang H Au1,2, Courtney C Cavalieri2, David D Stenehjem1,2

  • 11 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|October 15, 2016
PubMed
Summary

Ceritinib offers a potent alternative for anaplastic lymphoma kinase-positive non-small cell lung cancer patients progressing on or intolerant to crizotinib. This targeted therapy shows improved antitumor activity, addressing resistance to earlier treatments.

Keywords:
Ceritinibanaplastic lymphoma kinasenon-small cell lung cancer

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Experiment Videos

Last Updated: Mar 13, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) treatment increasingly relies on targeted therapies.
  • Anaplastic lymphoma kinase (ALK) inhibitors like crizotinib are crucial for ALK-positive NSCLC.
  • Acquired resistance to crizotinib affects nearly half of treated patients, necessitating alternative therapies.

Purpose of the Study:

  • To review the epidemiology, pathogenesis, and genetic alterations in NSCLC.
  • To detail the mechanism of action, clinical development, pharmacodynamics, and pharmacokinetics of ceritinib.
  • To evaluate ceritinib as a second-line treatment for ALK-positive metastatic NSCLC.

Main Methods:

  • Literature review of NSCLC, genetic alterations, and ceritinib's development.
  • Analysis of preclinical data comparing ceritinib and crizotinib.
  • Summary of clinical trial data supporting ceritinib's accelerated approval.

Main Results:

  • Ceritinib demonstrates more potent antitumor activity than crizotinib in preclinical models.
  • Accelerated approval was granted for ceritinib in 2014 for specific NSCLC patient populations.
  • Ceritinib provides an alternative for patients with limited treatment options after crizotinib failure.

Conclusions:

  • Ceritinib is an important second-line treatment option for ALK-positive metastatic NSCLC.
  • Targeted therapies and managing resistance are key advancements in NSCLC treatment.
  • Oncology clinical pharmacists must stay updated on novel anticancer agents like ceritinib.